Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

In the latest fracas over the burgeoning market for weight loss drugs, a compounding pharmacy has filed a lawsuit accusing ...

AbbVie CEO said that the company is now looking at candidates that provide sustained weight loss. ・The obesity drug market is ...

Delaware Attorney General Kathy Jennings is suing several drug manufacturers and pharmacy benefit managers for reported ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 4 includes Eli Lilly, Enterprise Products ...

Pharmaceutical companies are paying thousands of Indiana doctors to talk about GLP-1 drugs, a WRTV Investigation has ...

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly and Nvidia are putting up to $1 billion on the table to see whether generative AI can compress the decade-long slog ...